Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TACROLIMUS vs ELIDEL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Tacrolimus is a calcineurin inhibitor. It binds to FK506-binding protein 12 (FKBP12), forming a complex that inhibits calcineurin phosphatase activity. This prevents dephosphorylation and nuclear translocation of nuclear factor of activated T-cells (NFAT), thereby inhibiting transcription of interleukin-2 (IL-2) and other cytokines, leading to suppressed T-cell activation and proliferation.
Inhibits T-cell activation by binding to macrophilin-12 (FKBP-12) and inhibiting calcineurin, thereby blocking cytokine transcription.
Prophylaxis of organ rejection in patients receiving allogeneic liver, kidney, or heart transplants,Treatment of rejection in liver, kidney, and heart transplants,Off-label: Treatment of moderate to severe atopic dermatitis (topical),Off-label: Graft-versus-host disease (GVHD) prophylaxis and treatment
Atopic dermatitis unresponsive to or intolerant of other topical treatments,Off-label: psoriasis, vitiligo, rosacea, contact dermatitis, lichen sclerosus, cutaneous lupus erythematosus
0.1-0.2 mg/kg/day orally in two divided doses (immediate-release); 0.05-0.15 mg/kg/day orally once daily (extended-release); 0.01-0.05 mg/kg/day continuous IV infusion.
Apply a thin layer of 1% cream to affected areas twice daily.
Terminal elimination half-life is approximately 8.7-21.7 hours in healthy volunteers and 18-41 hours in liver transplant recipients. Prolonged half-life in hepatic impairment requires dose adjustments.
Terminal elimination half-life: 30–45 hours (mean 35 hours) following topical application; clinically, twice-daily dosing ensures therapeutic concentrations.
Primarily metabolized by cytochrome P450 3A4 (CYP3A4) and to a lesser extent by CYP3A5 in the liver and intestinal wall. It is a substrate of P-glycoprotein (ABCB1).
Metabolized primarily by CYP3A4; major metabolite O-demethylated pimecrolimus.
Primarily fecal (approximately 93%), with renal excretion accounting for about 2.4% of the unchanged drug. Biliary excretion is a minor route for metabolites.
Renal (negligible, <1% unchanged) and biliary/fecal (approximately 97% as metabolites); less than 1% of the dose is excreted renally as unchanged drug.
Approximately 99% bound, primarily to albumin and alpha-1-acid glycoprotein.
99% bound to plasma proteins (primarily albumin and alpha-1-acid glycoprotein).
Approximately 0.85-1.5 L/kg, reflecting extensive tissue distribution and binding to lymphocytes.
Vd ~ 10 L/kg (extensive tissue distribution); suggests significant extravascular binding and penetration into tissues.
Oral: about 17-25% (variable due to first-pass metabolism and food effects); topical: minimal systemic absorption (less than 5% in healthy skin).
Topical: Systemic bioavailability is approximately 4% (range 1–7%) of applied dose; absorption increases with extent of skin lesion and thickness of application.
No standard dose adjustment for renal impairment; monitor renal function closely and reduce dose if nephrotoxicity occurs. For GFR < 30 m L/min, consider dose reduction by 50% and close monitoring.
No dose adjustment required for any degree of renal impairment.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: reduce dose by 75%; monitor trough levels.
No formal studies in hepatic impairment; use caution in severe impairment.
0.15-0.3 mg/kg/day orally in two divided doses (immediate-release); 0.03-0.1 mg/kg/day continuous IV infusion; titrate to target trough levels.
Apply a thin layer of 1% cream twice daily for children aged 2 years and older; not indicated for children under 2 years.
Start at lower end of dosing range (0.05-0.1 mg/kg/day orally); monitor renal function and trough levels closely due to age-related decline in renal function.
No specific dose adjustment recommended; apply a thin layer of 1% cream twice daily as for adults.
Increased susceptibility to infection and the possible development of lymphoma. Only physicians experienced in immunosuppressive therapy and management of transplant patients should prescribe tacrolimus. Patients receiving tacrolimus should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources.
Long-term safety of topical calcineurin inhibitors has not been established; rare cases of malignancy (e.g., lymphoma, skin cancer) have been reported; use should be limited to short-term and intermittent treatment.
Increased risk of lymphomas and other malignancies, particularly skin cancer,Increased susceptibility to infections, including opportunistic infections and reactivation of latent viruses (e.g., BK virus, CMV, EBV),Nephrotoxicity: acute and chronic renal impairment, monitor renal function closely,Neurotoxicity: tremors, headache, seizures, posterior reversible encephalopathy syndrome (PRES),Hyperkalemia: monitor serum potassium levels,Hypertension: monitor blood pressure and manage accordingly,Post-transplant diabetes mellitus: monitor blood glucose levels,Anaphylactic reactions: risk with intravenous formulation due to castor oil derivative (polyoxyl 60 hydrogenated castor oil) in some formulations,QT prolongation: caution in patients with risk factors or with drugs that prolong QT interval
Increased risk of infections (e.g., eczema herpeticum, varicella zoster); avoid use on malignant or premalignant skin conditions; lymphadenopathy; photosensitivity; not recommended in patients with Netherton syndrome; potential for systemic immunosuppression; monitor for local irritation.
Hypersensitivity to tacrolimus or any component of the formulation,Hypersensitivity to hydrogenated castor oil (present in some intravenous formulations)
Hypersensitivity to pimecrolimus or any component of the formulation; history of malignancy; application to areas of active infection; Netherton syndrome; immunocompromised patients.
Grapefruit and grapefruit juice increase tacrolimus levels by inhibiting CYP3A4 and must be avoided. High-fat meals decrease absorption; consistent timing relative to meals recommended.
No known food interactions. Avoid grapefruit juice as it may increase drug levels (CYP3A4 inhibition).
First trimester: Increased risk of congenital malformations including cardiac anomalies. Second and third trimesters: Risk of fetal growth restriction, preterm delivery, and neonatal hyperkalemia. Tacrolimus crosses the placenta.
FDA Pregnancy Category C. Systemic exposure is minimal after topical application, but animal studies have shown developmental toxicity. No adequate human studies; risk cannot be excluded. Avoid in pregnancy unless clearly needed.
Tacrolimus is excreted into breast milk. M/P ratio (concentration in milk:plasma) is approximately 0.3-0.9. It is recommended to use with caution; monitor infant for immunosuppression and tacrolimus trough levels.
Not recommended. Pimecrolimus is excreted in milk in animal studies; unknown in humans. M/P ratio not available. Potential for serious adverse reactions in nursing infants.
Increased dose requirements due to increased volume of distribution and clearance. Monitoring tacrolimus trough levels recommended every 1-2 weeks; dose adjustments to maintain therapeutic range (typically 5-15 ng/m L).
No dose adjustment necessary; use minimal amount to control symptoms. Systemic absorption is negligible, so pharmacokinetic changes in pregnancy do not alter dosing.
Monitor trough levels 2-3 days after dose changes; target 5-15 ng/m L for most indications. Use with caution in renal impairment due to nephrotoxicity. Strong CYP3A4 interaction potential; avoid grapefruit and adjust azole antifungals. Hypomagnesemia common; supplement as needed.
Topical calcineurin inhibitor for atopic dermatitis, reserved as second-line therapy for mild-to-moderate eczema due to boxed warning for rare malignancy risk. Apply thin layer only; avoid occlusive dressings. Do not use in immunocompromised patients. Intermittent use is recommended; continuous long-term use safety not established.
Take consistently with or without food, but do not switch between.,Avoid grapefruit and grapefruit juice.,Report signs of infection, tremors, or kidney issues (swelling, decreased urine).,Do not take any new medications without consulting your doctor.,Use sun protection due to increased skin cancer risk.,Do not miss doses; if you do, take as soon as remembered unless near next dose.
Apply only to affected skin areas; avoid eyes, mouth, and open wounds.,Use for short durations; do not use continuously for extended periods.,Avoid sun exposure and tanning beds; use sunscreen on treated areas.,Do not cover treated skin with bandages or wraps unless instructed.,Report any signs of infection, skin burning, or new skin growths to your doctor.,This drug is for external use only; wash hands after application unless treating hands.,Do not use if you have a weakened immune system or active skin infection.
"Tacrolimus, a potent CYP3A4 inhibitor, significantly decreases the metabolism of citalopram, a CYP3A4 substrate, leading to elevated citalopram plasma concentrations. This pharmacokinetic interaction increases the risk of dose-dependent adverse effects such as QT prolongation, serotonin syndrome, and central nervous system toxicity. Clinical outcomes may include corrected QT (QTc) interval prolongation, increasing the risk of torsade de pointes, and enhanced serotonergic effects requiring careful monitoring."
"Tacrolimus, a calcineurin inhibitor, primarily induces nephrotoxicity through afferent arteriolar vasoconstriction and direct tubular injury. Etofenamate, a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reduces prostaglandin synthesis, leading to decreased renal blood flow and glomerular filtration rate. Concomitant use synergistically impairs renal function, increasing the risk of acute kidney injury, hyperkalemia, and hypertension, particularly in patients with preexisting renal impairment or volume depletion."
"Tacrolimus, a calcineurin inhibitor and CYP3A4 substrate, may inhibit the metabolism of isoflurophate, a long-acting cholinesterase inhibitor used in glaucoma. This interaction can lead to increased systemic exposure of isoflurophate, potentially exacerbating cholinergic side effects such as bradycardia, hypersalivation, and bronchospasm. Clinically, patients may experience enhanced toxicity, including prolonged muscle weakness or respiratory depression, especially in those with compromised hepatic function."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TACROLIMUS vs ELIDEL, answered by our medical review team.
TACROLIMUS is a Calcineurin Inhibitor that works by Tacrolimus is a calcineurin inhibitor. It binds to FK506-binding protein 12 (FKBP12), forming a complex that inhibits calcineurin phosphatase activity. This prevents dephosphorylation and nuclear translocation of nuclear factor of activated T-cells (NFAT), thereby inhibiting transcription of interleukin-2 (IL-2) and other cytokines, leading to suppressed T-cell activation and proliferation.. ELIDEL is a Topical Calcineurin Inhibitor that works by Inhibits T-cell activation by binding to macrophilin-12 (FKBP-12) and inhibiting calcineurin, thereby blocking cytokine transcription.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TACROLIMUS and ELIDEL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TACROLIMUS is: 0.1-0.2 mg/kg/day orally in two divided doses (immediate-release); 0.05-0.15 mg/kg/day orally once daily (extended-release); 0.01-0.05 mg/kg/day continuous IV infusion.. The standard adult dose of ELIDEL is: Apply a thin layer of 1% cream to affected areas twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TACROLIMUS and ELIDEL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TACROLIMUS is classified as Category D/X. First trimester: Increased risk of congenital malformations including cardiac anomalies. Second and third trimesters: Risk of fetal growth restriction, preterm delivery, and neonat. ELIDEL is classified as Category C. FDA Pregnancy Category C. Systemic exposure is minimal after topical application, but animal studies have shown developmental toxicity. No adequate human studies; risk cannot be ex. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.